DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20884/S-035

SUPPLEMENT APPROVAL

Boehringer-Ingelheim
Attention: Steven Berthel, Ph.D.
Associate Director, Regulatory Affairs
900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877-0368

Dear Dr. Berthel:

Please refer to your Supplemental New Drug Application (sNDA) dated 13 May 2015, received 13 May 2015, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Aggrenox (aspirin/extended release dipyridamole) 25 mg/200 mg Capsules.

This Prior Approval supplemental new drug application provides for changes to the WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS sections to add anagrelide (Agrylin) to the list of medications that could increase a patient's risk of bleeding if administered concomitantly, based on literature data. These changes are as follows:

FULL PRESCRIBING INFORMATION (FPI)

1. In Section 5.1 (**WARNINGS AND PRECAUTIONS – Risk of Bleeding**), the drug "anagrelide" was added to the list of example drugs that when administered concomitantly could increase the patient's risk of bleeding.

2. In Section 7.1 (**DRUG INTERACTIONS - Drug Interaction Study Information Obtained From Literature**), the following was added:

   "*Anagrelide*
   Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding."

3. Other minor editorial changes were made throughout the FPI.

PATIENT INFORMATION

4. In the section "**Tell your doctor about all the medicines you take**", "anagrelide [Agrylin®]" was added to the list of medications you should tell your doctor that you are taking.

5. Under, "**General information about AGGRENOX**", the text in red of the following and the QR code were added:

"For more information, go to www.Aggrenox.com, scan the code below or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906.

6. Other minor editorial changes were made throughout the PATIENT INFORMATION.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Alison Blaus, RAC
Senior Regulatory Health Project Manager
301-796-1138

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
11/09/2015